GlassScriptPhysician profile
Timothy Joseph Oconnor
NPI 1285081711
$2,450.45
in general payments reported to CMS, 2019-2025
23 companies · $684 in 2025
The $684 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $80.84 · 2023: $514 · 2024: $947 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.69 | 2021-2025 | |
| Lundbeck LLC | $320.99 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.37 | 2023-2025 | Caplyta |
| Alkermes, INC. | $249.56 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Synaptive Medical INC. | $172.78 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $137.38 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $121.21 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $107.94 | 2023-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $93.59 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Bausch Health US, LLC | $65.42 | 2023-2024 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $54.47 | 2023-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $52.39 | 2023-2024 | Spravato |
| Almatica Pharma LLC | $39.21 | 2024-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $36.68 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $31.44 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $29.41 | 2025 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $25.27 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $22.35 | 2023 | Jornay Pm |
| Allergan, INC. | $19.97 | 2021 | |
| Biogen, INC. | $17.99 | 2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $16.82 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $15.02 | 2023 | Xelstrym |
| Avion Pharmaceuticals | $13.50 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.